Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
OPKO Health (Nasdaq: OPK) will participate in the Jefferies Biotech on the Beach Summit March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will hold one-on-one investor meetings on Wednesday, March 11. Investors should contact their Jefferies representative to schedule meetings.
OPKO Health (NASDAQ: OPK) reported Q4 2025 results and 2026 guidance on Feb 26, 2026. Consolidated Q4 revenues were $148.5M vs $183.6M year-ago; Q4 net loss was $31.3M (‑$0.04 per share). Cash and equivalents were $369.1M at year-end. Key pipeline and partnerships: Regeneron multispecific collaboration (>$1B potential, >$200M program milestones), Merck EBV vaccine Phase 1 completed, BARDA-supported COVID antibody Phase 1 planned Q2 2026.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.
Senior management will host a business update, discuss results and provide financial guidance on a conference call and live webcast at 4:30 p.m. ET. Registration, dial-in numbers, webcast links and replay details are available for investors; telephone replay accessible through March 5, 2026.
OPKO Health (NASDAQ: OPK) and Entera Bio (NASDAQ: ENTX) expanded their collaboration to advance a first-in-class oral long-acting PTH (LA-PTH) once-daily tablet for hypoparathyroidism. The program is 50/50 owned and cost-shared, with an IND filing targeted for late 2026 after favorable PK/PD preclinical data.
The companies maintain a 60/40 ownership and cost split (OPKO/Entera) for the oral oxyntomodulin (OXM) program, with injectable Phase 1 data expected by late 2026. Steve Rubin joins Entera's board as Gerry Ostrov steps down.
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Management will host one-on-one investor meetings and take part in a fireside chat on Wednesday, January 14, 2026 at 1:30 p.m. PT. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website.
OPKO Health (Nasdaq: OPK) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City from December 2–4, 2025. Management will hold one-on-one investor meetings and appear in a fireside discussion on December 3, 2025 at 12:00 p.m. ET. Investors who want meetings are instructed to contact their Piper Sandler representative to schedule.
OPKO Health (NASDAQ: OPK) reported third-quarter 2025 results and business highlights on October 29, 2025, including a multi‑program research collaboration with Regeneron using ModeX MSTAR, with potential program milestones >$200M each and overall collaboration value potentially exceeding $1 billion. OPKO completed the sale of BioReference oncology assets to Labcorp for $225 million (including up to $32.5M earnout) and received $173.3M cash at closing. Consolidated Q3 revenue was $151.7M (down from $173.6M); operating income was $48.1M; net income was $21.6M ($0.03 diluted) which included a $101.6M gain on the asset sale. Cash and equivalents were $428.9M; $73.8M of share repurchases completed, $126.2M remaining.
ModeX Therapeutics (NASDAQ: OPK) announced a license and collaboration with Regeneron (NASDAQ: REGN) to discover and develop multispecific antibodies using ModeX’s MSTAR platform and Regeneron’s proprietary binders.
Key terms: an upfront payment of $7 million, per-molecule product selection, clinical and commercial milestone payments exceeding $200 million per selected molecule, tiered global net sales royalties up to the low double digits, and an overall collaboration value that potentially exceeds $1 billion if multiple products advance. Regeneron will fund and lead preclinical, clinical development and commercialization for products it advances. Targeted indications include immunology, oncology and metabolic diseases.
ModeX Therapeutics (NASDAQ: OPK) announced dosing of the first patient in a Phase 1/2a clinical trial (NCT07110584) of MDX2004, a first-in-class trispecific antibody-fusion protein designed as a T cell "rejuvenator."
MDX2004 engages CD3, CD28 and binds 4-1BB as a ligand to stimulate stem and memory T cells; the trial will evaluate safety, tolerability and biologic activity in advanced cancers. Two MDX2004 posters are scheduled at the SITC Annual Meeting, Nov 5-9, 2025.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and nine months ended September 30, 2025 after U.S. market close on Wednesday, October 29, 2025.
Senior management will give a business update and discuss results and financial guidance on a conference call and live audio webcast starting at 4:30 p.m. Eastern on October 29. OPKO encourages pre-registration to receive a unique PIN for immediate access; dial-in options are 833-630-0584 (U.S.) and 412-317-1815 (International). A telephone replay is available until November 5, 2025 (passcode 8678248), and a webcast replay will be posted about one hour after the live call.